Annals of the Russian academy of medical sciencesAnnals of the Russian academy of medical sciences0869-60472414-3545"Paediatrician" Publishers LLC134210.15690/vramn1342Research ArticleA Randomized Safety Study of 13-Valent Pneumococcal Conjugated Vaccine and Post-Vaccination Immune Response to <i> Streptococcus pneumoniae </i> Serotypes in Adult Patients with Bronchial Asthma and Chronic Obstructive Pulmonary DiseaseKostinovMichael P.<p>MD, PhD, Professor, head of the laboratory of immunoprophylaxis and immunotherapy of allergic diseases; Professor of the Department of epidemiology and modern technologies of vaccination</p>monolit.96@mail.ruhttps://orcid.org/0000-0002-1382-9403ProtasovAnrey D.<p>MD, PhD, Associate Professor of the Department of General and clinical Microbiology, immunology and Allergology</p>crosss82@mail.ruhttps://orcid.org/0000-0001-8452-5776ZhestkovAlexandr V.<p>MD, PhD, Professor, head of the Department of General and clinical Microbiology, immunology and Allergology</p>avzhestkov2015@yandex.ruhttps://orcid.org/0000-0002-3960-830XYastrebovaNatalya E.<p>MD, PhD, Professor, head of the laboratory of immunochemical diagnostics</p>yastreb03@rambler.ruhttps://orcid.org/0000-0002-6911-1345KostinovAnton M.<p>student</p>mono469@gmail.comhttps://orcid.org/0000-0001-9665-1382VlasenkoAnna E.<p>PhD in Technical Sciences</p>vlasenkoanna@inbox.ruhttps://orcid.org/0000-0001-6454-4216PolishhukValentina B.<p>MD, PhD, senior researcher at the laboratory of immunotherapy and immunotherapy of allergic diseases</p>polischook@mail.ruhttps://orcid.org/0000-0003-0533-0909KostinovaAristitsa M.<p>PhD student</p>aristica_kostino@mail.ruhttps://orcid.org/0000-0002-0584-2376KorovkinaElena S.<p>MD, PhD, senior researcher at the laboratory of immunotherapy and immunotherapy of allergic diseases</p>eskorovkina@yandex.ruhttps://orcid.org/0000-0001-8896-5808RyzhovAlexey A.<p>MD, PhD, senior researcher at the laboratory of immunotherapy and immunotherapy of allergic diseases</p>5231201@mail.ruhttps://orcid.org/0000-0002-7759-2003Shmit'koAnna D.<p>MD, PhD, senior researcher at the laboratory of immunotherapy and immunotherapy of allergic diseases</p>violadellanna@gmail.comhttps://orcid.org/0000-0002-7280-6877I.I. Mechnikov Research Institute of Vaccines and SeraI.M. Sechenov First Moscow State Medical University (Sechenov University)Samara State Medical UniversityLomonosov Moscow State UniversityNovokuznetsk State Institute for Further Training of Physicians — Branch Campus of Russian Medical Academy of Continuous ProfessionalInstitute of Immunology FMBA of Russia030920217633243342104202001072021Copyright © 2021, "Paediatrician" Publishers LLC2021<p><strong><em>Background. </em></strong><em>Vaccination against pneumococcal infection is one of the priorities in improving the quality of treatment and prevention measures in adults with various pathologies. The effectiveness of vaccination is directly related to the individuals ability to form an adequate specific immunity. <strong>Aims</strong> the aim of the study was to assess the level of post-vaccination antibodies to capsular polysaccharides of S. pneumoniae in adult patients with bronchial asthma (BA) or chronic obstructive pulmonary disease (COPD) after administration of 13-valent conjugated pneumococcal vaccine (PCV13). <strong>Materials and methods.</strong> The ELISA method was used to determine the level of IgG antibodies to 12 capsular polysaccharides serotypes 1, 3, 4, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F of S. pneumoniae that are part of PCV13, and 2 serotypes 9N, 15B that are not part of the vaccines using research test systems developed on the basis of the I.I. Mechnikov Research Institute of Vaccines and Sera. Groups of adult patients 32 patients with BA and 33 with COPD who received basic treatment according to accepted international standards. The comparison group consists of 20 healthy patients who do not have comorbidities. In patients, vaccination was performed outside the acute period of the disease using PCV13. <strong>Results.</strong> Vaccination of PCV13 patients with BA and COPD does not lead to the development of exacerbations of the underlying disease, while unusual symptoms in the post-vaccination period, provided for by the drugs instructions, can rarely develop. A comparative analysis of changes in IgG antibodies conducted after 6 weeks relative to the initial level of IgG antibodies to S. pneumoniae capsular polysaccharides in adult patients and healthy vaccinated PCV13 showed the same increase in specific antibodies to 12 serotypes of pneumococcus. The difference was found only in relation to IgG antibodies to a mixture of polysaccharides included in the PCV13 vaccine, which were registered higher in patients with BA and COPD in the post-vaccination period (p 0.001) than in healthy patients. <strong>Conclusions. </strong>PCV13 vaccination of patients with BA and COPD is safe and is accompanied by the synthesis of IgG antibodies to capsular polysaccharides serotypes of S. pneumoniae similarly to the healthy group.</em></p>BACOPDpneumococcal conjugated vaccinepost-vaccination immunityantibodies to S. pneumoniae serotypesбронхиальная астмаХОБЛпневмококковая конъюгированная вакцинапоствакцинальный иммунитетантитела к серотипам S. pneumoniae[Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the global burden disease study 2016. Lancet Infect Dis. 2018;18(11):1191–1210. doi: https://doi.org/10.1016/S1473-3099(18)30310-4][Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024. doi: https://doi.org/10.1093/ofid/ofu024][Hanguet G, Krizova P, Valentiner-Branth P, et al. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. Thorax. 2019;74(5):473–482. doi: https://doi.org/10.1136/thoraxjnl-2018-211767][Webber C, Patton M, Patterson S, et al. Exploratory efficacy endpoints in the community-acquired pneumonia immunization trial in adults (CAPiTA). Vaccine. 2017;35(9):1266–1272. doi: https://doi.org/101016/vaccine 2017.01.032][Gessner BD, Jiang Q, Van Werkhoven CH, et al. A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease oucomes from a randomized clinical trial in the Netherlands. Vaccine. 2018:S0264-410X(18)30763-1. doi: https://doi.org/10.1016/jcaccine 2018.05.097][McLaughlin JM, Swerdlow DL, Khan F, et al. Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States. Hum Vaccin Immunother. 2019;15(4):841–849. doi: https://doi.org/10.1080/21645515.2018.1564434][Брико Н.И., Симонова Е.Г., Костинов М.П., и др. Иммунопрофилактика пневмококковых инфекций: учебно-метод. пособие / под ред. Н.И. Брико. — М., 2013. — 278 c. [Brico NI, Simonova EG, Kostinov MP, et al. Immunoprophylaxis of pneumococcal infections. Educational-methodical manual. N.I. Bricaud (ed.). Moscow; 2013. 278 p. (In Russ.)]][Гаращенко Т.И., Костинов М.П., Ильенко Л.И., и др. Профилактическое и терапевтическое использование гемофильной и пневмококковой вакцин у часто и длительно болеющих детей с рецидивирующими средними отитами // Вопросы современной педиатрии. — 2006. — № 5 (5). — С. 24–28. [Garashchenko TI, Kostinov MP, Ilienko LI, et al. Preventive and therapeutic application of hib and pneumococcal vaccines among children, who are prone to frequent and prolonged recurrent otites media. Current Pediatrics. 2006;5(5):24–28. (In Russ.)].][Ильенко Л.И., Костинов М.П., Гаращенко М.В., и др. Иммунизация вакцинами для профилактики пневмококковой, гемофильной инфекции и гриппа у часто и длительно болеющих детей с хронической и часто рецидивирующей неспецифической инфекционной патологией бронхолегочной системы // Вопросы современной педиатрии. — 2006. — № 5 (4). — C. 27–30. [Ilienko LI, Kostinov MP, Garashchenko MV, et al. Vaccine immunization for prevention of pneumococcal, haemophilus influenzae and flu among sickly children, who often suffer from persistent heterospecific infectious pathology of the bronchopulmonary system. Current Pediatrics. 2006;5(4):27–30. (In Russ.)]][Руководство по клинической иммунологии в респираторной медицине / под ред. М.П. Костинова, А.Г. Чучалина. — М.: АТМО, 2016. — 128 c. [Manual on clinical immunology in respiratory medicine. Eds. M.P. Kostinov, A.G. Chuchalin. Мoscow; 2016. 128 p. (In Russ.)]][Чучалин А.Г., Биличенко Т.И., Осипова Г.Л., и др. Вакцинопрофилактика болезней органов дыхания в рамках первичной медико-санитарной помощи населению. Клинические рекомендации // Пульмонология. Приложение. — 2015. — № 2 (25). — С. 1–19. [Chuchalin AG, Bilichenko TN, Osipova GL, et al. Vaccine prevention of respiratory diseases in the framework of primary health care to the population. Pulmonology. 2015;2(25):1–19. (In Russ.)]][Рыжов А.А., Костинов М.П., Магаршак О.О. Применение вакцин против пневмококковой и гемофильной типа b инфекций у лиц с хронической патологией // Эпидемиология и вакцинопрофилактика. — 2004. — № 6 (19). — С. 24–27. [Ryzhov AA, Kostinov MP, Magarshak OO. Use of vaccines against pneumococcal and hemophilic type b infections in persons with chronic pathology. Epidemiology and Vaccinoprophylaxis. 2004;6(19):24–27. (In Russ.)]][Соловьева И.Л., Костинов М.П., Кусельман А.И. Особенности вакцинации детей с измененным преморбидным фоном против гепатита В, кори, эпидемического паротита: монография. — Ульяновск: УлГУ, 2006. — 296 с. [Solovieva IL, Kostinov MP, Kuselman AI. Features of vaccination of children with a changed premorbid background against hepatitis B, measles, mumps: monograph. Ulyanovsk; 2006. 296 p. (in Russ.)]][Костинов М.П. Клинико-иммунологические особенности вакцинации АКДС-М и АДС-М препаратами детей с аллергическими заболеваниями: автореф. дис. … д-ра мед. наук. — М., 1993. — 47 c. [Kostinov M.P. Clinical-immune features of DTP-M and DT-M vaccination for children with allergy: abstract of doctoral theme. Moscow; 1993. 47 p. (In Russ.)]][Маркелова Е.В., Гущина Я.С., Костинов М.П., и др. Клинико-иммунологический эффект вакцинации «ПНЕВМО 23» детей с атопической бронхиальной астмой // Журнал микробиологии эпидемиологии и иммунобиологии. — 2005. — № 2. — C. 83–85. [Markelova EV, Gushchina YaS, Kostinov MP, et al. Clinical and immunological effect produced by vaccination with “Pneumo 23” of children with atopic bronchial asthma. Journal of Microbiology, Epidemiology and Immunobiology. 2005;2:83–85. (In Russ.)]][Протасов А.Д., Жестков А.В., Лаврентьева Н.Е., и др. Эффект комплексной вакцинации против пневмококковой, гемофильной типа b инфекций и гриппа у пациентов с хронической обструктивной болезнью легких // Журнал микробиологии, эпидемиологии и иммунобиологии. — 2011. — № 4. — С. 80–84. [Protasov AD, Zhestkov AV, Lavrenteva NE, et al. Effect of complex vaccination against pneumococcal, haemophilus type b infections and influenza in patients with chronic obstructive pulmonary disease. Journal of Microbiology, Epidemiology and Immunobiology. 2011;4:80–84. (In Russ.)]][Лукачев И.В., Костинов М.П., Шабалина С.В. Бронхиальная астма и бактериальная инфекция // Эпидемиология и инфекционные болезни. — 2003. — № 3. — C. 48–52. [Lukachev IV, Kostinov MP, Shabalina SV. Bronchial asthma and bacterial infection. Epidemiology and Infectious Diseases. 2003;3:48–52. (In Russ.)]][Рыжов А.А., Катосова Л.К., Костинов М.П., и др. Оценка влияния бактериальных вакцин «PNEUMO 23» и «ACT-HIB» на течение хронического воспалительного процесса органов дыхания у детей // Журнал микробиологии, эпидемиологии и иммунологии. — 2005. — № 3. — C. 84–87. [Ryzhov AA, Katosova LK, Kostinov МP, et al. Еvaluation of the influence of the bacterial vaccines PNEUMO-23 and ACT-HIB on the course of the chronic inflammatory process of the respiratory organs in children. Journal of Microbiology, Epidemiology and Immunobiology. 2005;3:84–87. (In Russ.)]][Ястребова Н.Е., Грищенко Н.В., Костинов М.П., и др. Опыт применения пневмококковых вакцин для изучения гуморального иммунитета // Журнал микробиологии, эпидемиологии и иммунологии. — 2012. — № 2. — С. 12–17. [Yastrebova NE, Grischenko NV, Kostinov MP, et al. Experience of application of pneumococcus vaccines for studies of humoral immunity. Journal of Microbiology, Epidemiology and Immunobiology. 2012;2:12–17. (In Russ.)]][Ванеева Н.П., Ястребова Н.Е. Специфический иммунный ответ к отдельным капсульным полисахаридам Streptococcus Pneumoniae у здоровых доноров крови и лиц, иммунизированных пневмококковыми вакцинами // Журнал микробиологии, эпидемиологии и иммунобиологии. — 2015. — № 5. — С. 20–26. [Vaneeva NP, Yastrebova NE. Specific immune response to certain capsule polysaccharides of Streptococcus pneumoniae in healthy blood donors and individuals with immunized with pneumococcal vaccines. Journal of Microbiology, Epidemiology and Immunobiology. 2015;5:20–26. (In Russ.)]][Протасов А.Д., Костинов М.П. Способ активации факторов противовирусной защиты у пациентов с хронической обструктивной болезнью легких. Патент на изобретение № 2591809. 2016:8. [Protasov AD, Kostinov MP. Method of enhancing non specific protection factors activity in patients with chronic obstructive pulmonary disease. Patent for invention No. 2591809. 2016:8]. Available from: https://findpatent.ru/patent/259/2591809.html][Протасов А.Д., Костинов М.П. Способ усиления активности факторов неспецифической защиты у пациентов с хронической обструктивной болезнью легких. Патент на изобретение № 2600838. 2016:8. [Protasov AD, Kostinov MP. A method of enhancing the activity of non-specific protection factors in patients with chronic obstructive pulmonary disease. Patent for invention No. 2600838. 2016:8]. Available from: https://findpatent.ru/patent/260/2600838.html][Протасов А.Д., Жестков А.В., Костинов М.П., и др. Способ формирования иммунологической памяти к антигенам Streptococcus pneumoniaeу пациентов с хронической обструктивной болезнью легких. Патент на изобретение № 2544168. 2015:6. [Protasov A.D., Zhestkov A.V., Kostinov M.P., et al. Method for forming immunological memory to Streptococcus pneumoniae antigens in patients with chronic obstructive pulmonary disease. Patent for invention No. 2544168. 2015:6.]. Available from: https://findpatent.ru/patent/254/2544168.html][Dagan R. Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation. Expert Rev Vaccines. 2019;18(6):641–661. doi: https://doi.org/10.1080/14760584.2019.1627207][McLaughlin JM, Jiang Q, Gessner BD, et al. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis. Vaccine. 2019;37(43):6310–6316. doi: https://doi.org/10.1016/j.vaccine.2019.08.059][Jackson LA, Gurtman A, van Cleeff, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults. Vaccine. 2013;31:3577–3584. doi: https://doi.org/10.1016/j.vaccine.2013.04.085][Frenck RW Jr, Gurtman A, Rubino J, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012;19(8):1296–1303. doi: https://doi.org/10.1128/CVI.00176-12][Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine. 2014;32(20):2364–2374. doi: https://doi.org/10.1016/j.vaccine.2014.02.002.]